


Does PDAC have an autograph? Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer with ROC AUC values above 0.95

> Laura Chirica, PhD Immunovia, Sweden



Contents


IMMray[™] Technology IMMray[™] PanCan-d Pancreatic Cancer Test results so far Prospective validation studies Summary and a look into the future






IMMray[™] Technology

Combining multiple immune system and tumor biomarkers from a single blood sample can reliably detect early stage PDAC






IMMray[®] Technology - Production







Combine the intensities for individual antibodies mathematically to yield a decision value that indicates a *Positive* or *Negative* result



Distinguishing PDAC from Healthy Controls 2018

Identified Stage I & II PDAC with 96% accuracy JOURNAL OF CLINICAL ONCOLOGY BIOLOGY OF NEOPLASIA Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer Linda D. Mellby, Andreas P. Nyberg, Julia S. Johansen, Christer Wingren, Børge G. Nordestgaard, Stig E. Bojesen, Breeana L. Mitchell, Brett C. Sheppard, Rosalie C. Sears, and Carl A.K. Borrebaeck Healthy Author affiliations and support information A B S T R A C T (if applicable) appear at the end of this PDAC Stage I and II article. Purpose Published at ico.org on August 14, 2018. Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of < 10% Clinical trial information: NCT03311776. because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of Corresponding author: Carl A.K. blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived Borrebaeck, DSc, Department of Immunotechnology and CREATE Health from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This Translational Cancer Center, Lund biomarker signature was validated subsequently in an independent patient cohort.

Patients and Methods


University, Medicon Village Bldg. 406, SE 223 81 Lund, Sweden; e-mail: carl.

borrebaeck@immun.lth.se.



Validating the Signature in two different cohorts: Scandinavian followed by US Stage I and II

- Sensitivity and specificity were very high for discriminating 250 samples Stage I and Stage II PDAC patients from 1000 controls.
- ROC curve for Stage I and Stage II PDAC patients versus controls showed an AUC of 0.96 for the **Scandinavian** cohort
- ROC curve for Stage I and Stage II PDAC patients versus controls showed an AUC of 0.96 for the **US** cohort



Mellby LD et al. J Clin Oncol. 2018: DOI: 10.1200/JCO.2017.77.6658




Optimization Study 2019

- A useful clinical test needs to be able to distinguish individuals with PDAC from patients with other relevant diseases, especially:
 - Patients with non-specific but concerning symptoms associated with PDAC (e.g. back or stomach pain, fatigue, digestive problems, weight loss)
 - New onset type II diabetes after age 50
- Partnered with University College London, University of Pittsburgh and Växjö Central Hospital, Sweden to obtain freshly collected patient samples to assess IMMray[™] performance in these patient populations
- Also investigated if adding CA19-9 to our signature would enhance IMMray[™] performance



Optimization Study Results PDAC vs Symptomatic, Diabetic Controls




		PE	DAC		Controls		
	Stage I	Stage II	Stage III	Stage IV	Healthy controls	Symptomatic controls (without diabetes)	Diabetes controls
No.	20	34	21	61	217	480	90



Healthy vs PDAC


Results combining IMMray[™] PanCan-d and CA19-9





Diabetes vs PDAC


Results combining IMMray[™] PanCan-d and CA19-9






Symptomatic vs PDAC

Results combining IMMray[™] PanCan-d and CA19-9





Healthy, Diabetic and Symptomatic Controls vs Early Stage PDAC Results combining IMMray[™] PanCan-d and CA19-9





IMMray[™] PanCan-d and disease progression

	mptomatic	Early symptoms Primary care evaluation	Symptoms and positive imaging HPB / Gastro clinic	Pancreatic cancer recurrence HPB / Gastro		
Familiar / hereditary individuals in screening programs		Frontline diagnostics / A	Frontline diagnostics / Adjunct diagnostics			
High risk screening test to work in conjunction with existing imaging tests to improve sensitivity and specificity		To aid /confirm the diagnosis of syn i.e. New onset	To help identify / monitor the recurrence of the pancreatic cancer			
	PanFAM-1	PanSYM-1		Not addressed		
		PanDIA-1				



3 high risk groups for pancreatic cancer

Hereditary Familia Familiar autosomal ≥ 2 close fam members Familiar non-autosomal ≥ 3 close fam members BRCA1/2 Hereditary FAMMM p16, CDKN2A Peutz Jeghers Lynch Syndrome Hereditary pancreatitis 2-132 risk of developing pancreatic cancer



- NEW ONSET DIABETES
 TYPE II AFTER 50 YRS
 OF AGE
- 8-10 Risk of developing pancreas cancer 1-3 yea after diagnosis



- Depression
- Indigestion/Nausea
- Jaundice
- Mid back pain
- Upper abdominal pain
- Pain on eating
- Fatigue
- Unexplained weight loss
- Diabetes



Prospective validation studies

27 sites from Europe and USA


3 large pancreatic cancer clinical studies: PanFAM-1, PanSYM-1 and PanDIA-1

Totally covering >10 000 high risk subjects





Important Next Steps Toward Launch





Summary

- Successful optimization of IMMray[™] PanCan-d in combination with CA 19-9 leads to AUC ROC >0.96 when differentiating PDAC from symptomatic patients, diabetics, and healthy controls
 - Findings have significant clinical implications for individuals attending primary and secondary care units with non-specific but concerning symptoms where PDAC may be suspected
- Completion of Commercial Test Model study, verification and validation are on track to offer IMMray[™] PanCan-d Q3 2020 at our IMMray Dx Laboratories in Marlborough, MA followed by IVD CE mark at IMMray Dx Laboratories in Lund, Sweden.
- Prospective clinical validation studies for IMMray[™] PanCan-d with individuals from the three major risk groups are ongoing to provide the necessary clinical evidence for regulatory approval and national reimbursement



Immunovia sites

Headquarters staff



Reference lab & production, Lund, SE



IMMray[™] Dx Laboratories



Reference lab, Boston, USA












Immunovia supporting pancreatic cancer awareness walks in US covering around 25,000 people in one year





Thank you!



Sunset, Öresund bridge (between Sweden and Denmark)